A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancer
Ontology highlight
ABSTRACT: Interventions: Irinotecan (100 mg/m2) and panitumumab (6 mg/kg) on days 1 and 15 and S-1 (40–60 mg according to body surface area) twice daily for 2 weeks, repeated every 4 weeks.
Primary outcome(s): Completion rate of protocol therapy
Study Design: Single arm Non-randomized
DISEASE(S): Colonrectal Cancer
PROVIDER: 2620105 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA